Research graph
References from Ex vivo expansion reshapes invariant natural killer T-cell state, function, and therapeutic fitness. Local targets link to admitted publications; unresolved targets remain external evidence.
Innate iNKT cells: from biological insight to clinical impact
10.3389/fimmu.2025.1653183 · 2025 · External reference
Antigen recognition by CD1d-restricted NKT T cell receptors
10.1016/j.smim.2009.10.004 · 2010 · External reference
Methods for detection, isolation and culture of mouse and human invariant NKT cells
10.1038/nprot.2007.515 · 2008 · External reference
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells
10.1038/sj.leu.2402943 · 2003 · External reference
Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein
10.1084/jem.20030324 · 2003 · External reference
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer
10.1084/jem.20042280 · 2005 · External reference
Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity
10.1111/j.1600-065x.2007.00561.x · 2007 · External reference
Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy
10.1182/blood.2022016201 · 2023 · External reference
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy
10.3389/fimmu.2025.1625426 · 2025 · External reference
Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia
10.1182/blood.2025029302 · 2026 · External reference
Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia
10.1038/s41375-026-02930-5 · 2026 · External reference
Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation
10.1111/j.1537-2995.2009.02395.x · 2010 · External reference
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism
10.1182/blood-2010-08-303008 · 2011 · External reference
CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells
10.1182/blood-2014-05-576017 · 2014 · External reference
Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality
10.1182/blood-2014-11-612762 · 2015 · External reference
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
10.1182/blood-2011-11-389304 · 2012 · External reference
Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11
10.1111/j.1365-2567.2007.02647.x · 2007 · External reference
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load
10.1002/ijc.20998 · 2005 · External reference
Expansion of human iNKT cells ex vivo
10.1007/978-1-0716-1775-5_11 · 2021 · External reference
Human and mouse iNKT cell expansion and engineering with viral vectors
2025 · External reference
Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells
10.1097/01.cji.0000199197.35964.8a · 2006 · External reference
Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15
10.1016/s0022-1759(00)00272-6 · 2001 · External reference
Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
10.1186/1471-2172-9-71 · 2008 · External reference
CD1d-invariant natural killer T cell-based Cancer immunotherapy: alpha-galactosylceramide and beyond
10.3389/fimmu.2018.01519 · 2018 · External reference
Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
10.1371/journal.pone.0261727 · 2021 · External reference
Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease
10.1016/j.jcyt.2018.05.007 · 2018 · External reference
Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop
10.1002/eji.200737389 · 2008 · External reference
IL-7 during antigenic stimulation using allogeneic dendritic cells promotes expansion of CD45RA(−)CD62L(+)CD4(+) invariant NKT cells with Th-2 biased cytokine production profile
10.3389/fimmu.2020.567406 · 2020 · External reference
Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials
10.1097/01.cji.0000163593.66910.ad · 2005 · External reference
Good manufacturing practice and clinical-grade human embryonic stem cell lines
10.1093/hmg/ddn079 · 2008 · External reference
Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells
2012 · External reference
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
10.1172/jci83476 · 2016 · External reference
Human cell-based artificial antigen-presenting cells for cancer immunotherapy
10.1111/imr.12129 · 2014 · External reference
Cellular therapy: adoptive immunotherapy with expanded natural killer cells
10.1111/imr.12793 · 2019 · External reference
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy
10.1158/0008-5472.can-08-3712 · 2009 · External reference
Large-scale expansion of Vgamma9Vdelta2 T cells with engineered K562 feeder cells in G-rex vessels and their use as chimeric antigen receptor-modified effector cells
10.1016/j.jcyt.2017.12.014 · 2018 · External reference
Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges
10.3389/fmed.2018.00150 · 2018 · External reference
Good manufacturing practice-compliant production and lot-release of ex vivo expanded regulatory T cells as basis for treatment of patients with autoimmune and inflammatory disorders
10.3389/fimmu.2017.01371 · 2017 · External reference
Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility
10.1186/s12967-025-06400-x · 2025 · External reference
Nanoscale artificial antigen presenting cells for T cell immunotherapy
10.1016/j.nano.2013.06.015 · 2014 · External reference
Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity
10.1016/j.jcyt.2020.01.011 · 2020 · External reference
CAR-T cell expansion platforms yield distinct T cell differentiation states
10.1016/j.jcyt.2024.03.003 · 2024 · External reference
Efficient regeneration of human Valpha24(+) invariant natural killer T cells and their anti-tumor activity in vivo
10.1002/stem.2465 · 2016 · External reference
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
10.1186/s41232-023-00275-5 · 2023 · External reference
Cellular adjuvant properties, direct cytotoxicity of re-differentiated Valpha24 invariant NKT-like cells from human induced pluripotent stem cells
10.1016/j.stemcr.2016.01.005 · 2016 · External reference
Efficient production of functional human NKT cells from induced pluripotent stem cells - reprogramming of human Valpha24(+)iNKT cells
10.21769/bioprotoc.2277 · 2017 · External reference
Development of a practical GMP-compliant manufacturing process for T cell-derived induced pluripotent stem cells
10.1016/j.jcyt.2025.102036 · 2026 · External reference
Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial
10.1038/s41467-025-66801-w · 2025 · External reference
Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop
10.1371/journal.pbio.1000402 · 2010 · External reference
CDR3beta sequence motifs regulate autoreactivity of human invariant NKT cell receptors
10.1016/j.jaut.2015.12.005 · 2016 · External reference
Tissue-specific shaping of the TCR repertoire and antigen specificity of iNKT cells
2019 · External reference
Recognition of beta-linked self glycolipids mediated by natural killer T cell antigen receptors
10.1038/ni.2076 · 2011 · External reference
Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment
2022 · External reference
Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer
10.1016/j.stem.2019.08.004 · 2019 · External reference
Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention
10.1186/s13287-022-02787-2 · 2022 · External reference
Targeting triple-negative breast cancer using cord-blood CD34(+) HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity
10.1186/s13045-025-01736-9 · 2025 · External reference
Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids
10.1038/nmeth.4237 · 2017 · External reference
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy
2021 · External reference
iPS-cell technology and the problem of genetic instability-can it ever be safe for clinical use?
10.3390/jcm8030288 · 2019 · External reference
Human induced pluripotent stem cells: from cell origin, genomic stability, and epigenetic memory to translational medicine
10.1093/stmcls/sxac020 · 2022 · External reference
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
10.1016/j.isci.2022.104859 · 2022 · External reference
Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method
10.1038/s41587-024-02226-y · 2025 · External reference
Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs
10.1093/intimm/dxh292 · 2005 · External reference
Interleukin-15 enhances the expansion and function of natural killer T cells from adult peripheral and umbilical cord blood
10.1016/j.cyto.2015.09.015 · 2015 · External reference
IL-21 selectively protects CD62L(+) NKT cells and enhances their effector functions for adoptive immunotherapy
10.4049/jimmunol.1800429 · 2018 · External reference
Alpha-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents
10.1371/journal.pone.0014374 · 2010 · External reference
Distinct and overlapping effector functions of expanded human CD4+, CD8alpha+ and CD4-CD8alpha- invariant natural killer T cells
10.1371/journal.pone.0028648 · 2011 · External reference
Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells
10.1002/eji.200737838 · 2008 · External reference
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
10.1182/blood-2013-11-541235 · 2014 · External reference
Enhancing neuroblastoma immunotherapies by engaging iNKT and NK cells
10.3389/fimmu.2020.00873 · 2020 · External reference
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production
10.4049/jimmunol.178.5.2827 · 2007 · External reference
Proinflammatory environment dictates the IL-17-producing capacity of human invariant NKT cells
10.4049/jimmunol.1003043 · 2011 · External reference
Rapamycin combined with TGF-beta converts human invariant NKT cells into suppressive Foxp3+ regulatory cells
10.4049/jimmunol.1102281 · 2012 · External reference
Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection
10.1084/jem.20102555 · 2011 · External reference
Invariant NKT cells amplify the innate immune response to lipopolysaccharide
10.4049/jimmunol.178.5.2706 · 2007 · External reference
Human invariant natural killer T cells acquire transient innate responsiveness via histone H4 acetylation induced by weak TCR stimulation
10.1084/jem.20111024 · 2012 · External reference
Interleukin-12 and interleukin-2-induced invariant natural killer T-cell cytokine secretion and perforin expression independent of T-cell receptor activation
10.1046/j.1365-2567.2003.01701.x · 2003 · External reference
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
10.1038/s41467-023-44310-y · 2024 · External reference
IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells
10.1093/intimm/dxn060 · 2008 · External reference
Alpha-GalCer and iNKT cell-based Cancer immunotherapy: realizing the therapeutic potentials
10.3389/fimmu.2019.01126 · 2019 · External reference
Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes
10.4049/jimmunol.165.8.4367 · 2000 · External reference
Glycolipid antigen induces long-term natural killer T cell anergy in mice
10.1172/jci24762 · 2005 · External reference
Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation
10.1093/intimm/dxq444 · 2010 · External reference
Alpha-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3
10.4049/jimmunol.1302623 · 2014 · External reference
Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis
10.1016/s1074-7613(00)80566-x · 1998 · External reference
Selective conditions are required for the induction of invariant NKT cell hyporesponsiveness by antigenic stimulation
10.4049/jimmunol.1500203 · 2015 · External reference
Loss of IFN-gamma production by invariant NK T cells in advanced cancer
10.4049/jimmunol.167.7.4046 · 2001 · External reference
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
10.1084/jem.20021650 · 2003 · External reference
IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset
10.1172/jci72308 · 2014 · External reference
Longitudinal analysis of invariant natural killer T cell activation reveals a cMAF-associated transcriptional state of NKT10 cells
2022 · External reference
KLRG+ invariant natural killer T cells are long-lived effectors
10.1073/pnas.1406240111 · 2014 · External reference
PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells
10.4049/jimmunol.0803648 · 2009 · External reference
Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis
10.1002/eji.201243185 · 2013 · External reference
Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment
10.1186/s12977-015-0142-z · 2015 · External reference
The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant natural killer T cell function
10.1038/s41598-023-36468-8 · 2023 · External reference
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
10.1038/s41591-023-02363-y · 2023 · External reference
TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion
10.1073/pnas.1905675116 · 2019 · External reference
TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion
10.1038/s41586-019-1325-x · 2019 · External reference
Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy
10.1016/j.immuni.2018.12.021 · 2019 · External reference
Distinct bioenergetic features of human invariant natural killer T cells enable retained functions in nutrient-deprived states
10.3389/fimmu.2021.700374 · 2021 · External reference
Immunometabolic activation of invariant natural killer T cells
10.3389/fimmu.2018.01192 · 2018 · External reference
beta-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy
10.1158/1078-0432.ccr-12-2169 · 2013 · External reference
Elevated hepatic CD1d levels coincide with invariant NKT cell defects in chronic hepatitis B virus infection
10.4049/jimmunol.1701801 · 2018 · External reference
IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects
10.1016/j.isci.2023.108597 · 2024 · External reference
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity
10.1016/j.ymthe.2026.01.001 · 2026 · External reference
LEF1 drives a central memory program and supports antitumor activity of natural killer T cells
10.1158/2326-6066.cir-22-0333 · 2023 · External reference
PRDM1 is a key regulator of the NKT-cell central memory program and effector function
10.1158/2326-6066.cir-24-0259 · 2025 · External reference
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
10.1038/s41591-020-1074-2 · 2020 · External reference
TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells
10.1126/sciimmunol.abn6563 · 2022 · External reference
CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences
10.1017/s1462399408000732 · 2008 · External reference
Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner
10.1111/cas.14428 · 2020 · External reference
iNKT: a new avenue for CAR-based cancer immunotherapy
10.1016/j.tranon.2022.101342 · 2022 · External reference
Tumor antigen escape from CAR T-cell therapy
10.1158/2159-8290.cd-18-0442 · 2018 · External reference
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety
10.1016/j.ymthe.2025.09.026 · 2025 · External reference
NKT cells Coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma
10.1158/1078-0432.ccr-19-0421 · 2019 · External reference
Traversing the bench to bedside journey for iNKT cell therapies
2024 · External reference
Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKvarepsilon complex inhibitor BX795
10.1186/s12967-020-02526-2 · 2020 · External reference
Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells
10.1089/hum.2021.173 · 2021 · External reference
The generation of CAR-transfected natural killer T cells for the immunotherapy of melanoma
10.3390/ijms19082365 · 2018 · External reference
Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance
10.3390/cancers11081198 · 2019 · External reference
Reprogramming human T cell function and specificity with non-viral genome targeting
10.1038/s41586-018-0326-5 · 2018 · External reference
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
10.1038/nm.3838 · 2015 · External reference
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
10.1038/s41571-021-00530-z · 2021 · External reference
Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction
2023 · External reference
Ex vivo expansion of Th2-polarizing immunotherapeutic iNKT cells from human peripheral blood
10.1007/978-1-0716-1775-5_13 · 2021 · External reference
Comparison of two flow cytometric methods for detection of human invariant natural killer T cells (iNKT)
2010 · External reference
Thymic development of human natural killer T cells: recent advances and implications for immunotherapy
10.3389/fimmu.2024.1441634 · 2024 · External reference
Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples
10.1002/eji.200425958 · 2005 · External reference
Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(−) subsets
10.1111/cei.12045 · 2013 · External reference
Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity
10.1182/blood-2001-12-0196 · 2002 · External reference
CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells
10.4049/jimmunol.171.5.2571 · 2003 · External reference
Unraveling the phenotypic states of human innate-like T cells: comparative insights with conventional T cells and mouse models
10.1016/j.celrep.2024.114705 · 2024 · External reference
Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues
10.1016/j.celrep.2025.115587 · 2025 · External reference
Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro
10.4049/jimmunol.1202223 · 2013 · External reference
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors
10.4049/jimmunol.0711086 · 2009 · External reference
Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells
10.1093/jleuko/qiad113 · 2024 · External reference
scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis
10.1016/j.canlet.2023.216149 · 2023 · External reference
Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans
10.1111/imcb.70074 · 2026 · External reference
The peripheral differentiation of human natural killer T cells
10.1111/imcb.12248 · 2019 · External reference
Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP
10.1182/blood-2012-09-456095 · 2013 · External reference
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)
10.1038/s41388-024-02948-y · 2024 · External reference
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome
10.1038/s41467-024-44905-z · 2024 · External reference
Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy
10.3389/fimmu.2024.1457771 · 2024 · External reference
Current challenges and strategies for chimeric antigen receptor-T-cell therapy for solid tumors
10.1615/critrevimmunol.2020036178 · 2021 · External reference
Barriers and opportunities for CAR T-cell targeting of solid tumors
10.1080/08820139.2022.2096463 · 2022 · External reference
Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors
2022 · External reference
Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy
10.1038/s41551-026-01629-3 · 2026 · External reference
Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors
2026 · External reference
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells
10.1038/mt.2013.262 · 2014 · External reference
Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
10.1038/s41388-025-03491-0 · 2025 · External reference
Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies
10.1016/j.jtct.2023.12.072 · 2024 · External reference
Pre-clinical evaluation of allogeneic 'off-the-shelf' CAR-iNKT cells targeting CD19 (ALA-101)-expressing hematological malignancies
10.1182/blood-2022-165516 · 2022 · External reference
A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and alpha-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: a study protocol
10.1371/journal.pone.0342387 · 2026 · External reference
The clinical landscape of CAR-engineered unconventional T cells
10.1016/j.trecan.2025.03.001 · 2025 · External reference
Potency assays and biomarkers for cell-based advanced therapy medicinal products
10.3389/fimmu.2023.1186224 · 2023 · External reference
A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer
10.1158/1078-0432.ccr-04-1453 · 2005 · External reference
A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer
10.1158/1078-0432.ccr-06-0114 · 2006 · External reference
A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer
10.4049/jimmunol.0800126 · 2009 · External reference
Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial
10.1158/1078-0432.ccr-16-0600 · 2017 · External reference
Ex-vivo alpha-galactosylceramide activation of NKT cells in humans and macaques
10.1016/j.jim.2012.05.019 · 2012 · External reference
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
10.1172/jci37869 · 2009 · External reference
Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence
10.1016/j.omtm.2024.101249 · 2024 · External reference
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
10.1016/j.ymthe.2024.04.005 · 2024 · External reference
Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein
10.1182/bloodadvances.2018028886 · 2019 · External reference
Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice
2008 · External reference
Development of novel invariant TCR-anchored bispecific engagers to enhance anti-cancer activity of iNKT cells
10.1182/blood-2023-190598 · 2023 · External reference
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
10.1007/s00262-012-1381-7 · 2013 · External reference
Serial stimulation of invariant natural killer T cells with covalently stabilized bispecific T-cell engagers generates antitumor immunity while avoiding anergy
10.1158/0008-5472.can-20-2219 · 2021 · External reference
